[Preliminary relationship between serum cystatin C level and Parkinson's disease]
Jinmin Xu1, Jing Chen, Chengjie Mao
1Department of Neurology, Second Affiliated Hospital, Soochow University, Suzhou 215004, China.
Objective:
To explore the role of serum cystatin C level in Parkinson's disease (PD) and evaluate the relationship between cystatin C level and clinical characteristics and different stages of PD.
Methods:
A total of 115 PD patients and 110 healthy controls were recruited. The results of such routine laboratory tests as triglyceride, cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), creatinine, urea, uric acid and cystatin C were assessed from fasting blood samples at our clinical laboratory center. They were further divided into subgroups according to Hoehn & Yahr (H&Y) staging. Statistical analysis was performed with SPSS version 17.0 software.
Results:
Compared to controls (0.96 ± 0.16 mg/L), the mean serum level of cystatin C was significantly higher in PD patients (1.06 ± 0.20 mg/L). Spearman's correlation analyses showed a positive and significant correlation between cystatin C levels and age as well as creatinine levels. Correlation was not found between cystatin C level and triglyceride, cholesterol, LDL, HDL, urea or uric acid. ANOVA analysis showed that cystatin C had a higher level during the middle and late stages of PD than that during the early stage.
Conclusion:
Cystatin C level may play an important role in the progression of PD.
More Related Videos
12:01Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
19:16The Importance of Correct Protein Concentration for Kinetics and Affinity Determination in Structure-function Analysis
Published on: March 17, 2010
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Serum Studies: Renal Function Tests
Parkinson Disease l: Introduction
Alterations in Muscle Tone lll
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
